Paid Clinical Trials Indianapolis
Discover 887 paid clinical trials in Indianapolis, Indiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Sponsor:
Takeda
Location:
Code:
NCT04844073
Conditions
Squamous Cell Cancer of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TAK-186
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Sponsor:
Gilead Sciences
Location:
Code:
NCT03547973
Conditions
Metastatic Urothelial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab Govitecan-hziy
Pembrolizumab
Cisplatin
Avelumab
Zimberelimab
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Sponsor:
Y-mAbs Therapeutics
Location:
Code:
NCT03363373
Conditions
Neuroblastoma
Eligibility Criteria
Sex: All
Age: 1+
Healthy Volunteers: Not accepted
Interventions
GM-CSF + Naxitamab
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Sponsor:
Washington University School of Medicine
Location:
Code:
NCT06384573
Conditions
Alzheimer's Disease
Dementia
Alzheimer's Disease, Familial
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
lecanemab
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
Sponsor:
Priovant Therapeutics, Inc.
Location:
Code:
NCT06431373
Conditions
Uveitis, Posterior
Uveitis, Intermediate
Uveitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Brepocitinib PO QD
Placebo PO QD
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Sponsor:
Dennis M. McNamara, MD, MS
Location:
Code:
NCT05180773
Conditions
Peripartum Cardiomyopathy, Postpartum
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bromocriptine
Placebo
Guideline Directed Medical Therapy for Heart Failure (GDMT)
Rivaroxaban
Second Placebo
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Sponsor:
Amgen
Location:
Code:
NCT05975073
Conditions
MTAP-null Non-Small-Cell Lung Cancer
MTAP-null Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AMG 193
IDE397
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Sponsor:
Escient Pharmaceuticals, Inc
Location:
Code:
NCT06077773
Conditions
Chronic Spontaneous Urticaria
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Oral EP262
Placebo
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Sponsor:
Children's Hospital Medical Center, Cincinnati
Location:
Code:
NCT02852031
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Eligibility Criteria
Sex: All
Age: 0 - 15
Healthy Volunteers: Not accepted
Interventions
Collaborative Learning Network
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Sponsor:
Kartos Therapeutics, Inc.
Location:
Code:
NCT05797831
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Navtemadlin
Navtemadlin Placebo